Premature Ejaculation Treatment Market to Surpass US$ 3.3 Bn Threshold by 2026

Global Premature Ejaculation Treatment Market, by Drug Type (Selective Serotonin Reuptake Inhibitors (SSRIs) (Dapoxetine, and Others), Phosphodiesterase Type 5 (PDE5) Inhibitors (Zertane, and Others), Topical Anesthetics, and Others), by Route of Administration (Oral and Topical), by Dosage Form (Pills, Spray, and Others), by Distribution Channel (Hospitals, Online Pharmacies, and Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 1.5 Bn in 2017, and is projected to exhibit a CAGR of 8.7% over the forecast period (2018 – 2026).

The global premature ejaculation treatment market is expected to show significant growth in the near future, owing to frequent launches and robust pipeline of novel products for treatment of premature ejaculation. Furthermore, rising prevalence of premature ejaculation among people due to unhealthy lifestyle is also expected to increase demand for its treatment products and fuel the market growth. For instance, in 2016, Regent Pacific Group Limited, a Hong Kong-based investment group, launched its product Fortacin in the U.K. Fortacin is a topical spray, which contains low doses of two anesthetics - lidocaine and prilocaine and is indicated for the treatment of premature ejaculation. In 2013, Menarini Group, an Italy-based pharmaceutical company, launched its Priligy (dapoxetine) in Singapore, indicated for the treatment of premature ejaculation. Priligy (dapoxetine) rapidly increases synaptic levels of serotonin in the central nervous system, thus improving symptoms of PE.

Browse 37 Market Data Tables and 40 Figures spread through 198 Pages and in-depth TOC on Premature Ejaculation Treatment Market by Drug Type (Selective Serotonin Reuptake Inhibitors (SSRIs) (Dapoxetine, and Others), Phosphodiesterase Type 5 (PDE5) Inhibitors (Zertane, and Others), Topical Anesthetics, and Others), by Route of Administration (Oral and Topical), by Dosage Form (Pills, Spray, and Others), by Distribution Channel (Hospitals, Online Pharmacies, and Retail Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026

To know the latest trends and insights prevalent in the Premature Ejaculation Treatment Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/premature-ejaculation-treatment-market-1956

Key players in the market are focusing on mergers and acquisitions, in order to launch new drugs indicated for the treatment of premature ejaculation. This is expected to aid in gaining a strong foothold in the market and also creates a lucrative opportunity for other key players to focus on and provide novel drugs for premature ejaculation treatment. For instance, in 2012, Furiex Pharmaceuticals, Inc. and Menarini Group entered into strategic partnership and signed a license agreement. According to the agreement, Furiex Pharmaceuticals, Inc. licensed Menarini rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America, and the Middle East.

Furthermore, rising prevalence of premature ejaculation is expected to drive demand for premature treatment products in the forecast period. For instance, according to the data published by Arab Journal of Urology in 2013, globally premature ejaculation affects up to 30% of men of all age group. Such high prevalence of premature ejaculation is expected to significantly increase demand for its treatment drug and drive the global premature ejaculation treatment market growth.

Key Takeaways of the Premature Ejaculation Treatment Market:

The global premature ejaculation treatment market is expected to exhibit a CAGR of 8.7% over the forecast period (2018 – 2026), owing to frequent product launches, approvals, and increasing research and development activities by key players for development of novel products.
North America held the dominant position in the global premature ejaculation treatment market and is expected to retain its dominance over the forecast period (2018 – 2026). This is due to increasing prevalence of premature ejaculation in the region. For instance, according to the American Urological Association (AUA), in U.S premature ejaculation is the most common form of male sexual dysfunction, affecting about 1 in three 3 aged 18 to 59.
Launches of novel premature ejaculation treatment drug by key players in the region is expected to drive significant growth of the Asia Pacific premature ejaculation treatment market in the near future. For instance, in 2013, Menarini Group, an Italy-based pharmaceutical company, launched its Priligy (dapoxetine) in Singapore.
Major players operating in the premature ejaculation treatment market are Regent Pacific Group Limited, Menarini Group, Furiex Pharmaceuticals, Inc., Absorption Pharmaceuticals, LLC, Ampio Pharmaceuticals, Inc., Aytu BioScience, NeuroHealing Pharmaceuticals Inc., and Dong-A Pharmaceutical Co., Ltd.